Page last updated: 2024-11-07

arg-3-hyp-7-phe-bradykinin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NPC 567: bradykinin receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

NPC-567 : A ten-membered oligopeptide comprising D-arginyl, L-arginyl, L-prolyl, (4R)-4-hydroxy-L-prolyl, glycyl, L-phenylalanyl, L-seryl, D-phenylalanyl, L-phenylalanyl and L-arginine residues joined in sequence. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID119343
CHEMBL ID446325
CHEBI ID73294
MeSH IDM0150290

Synonyms (26)

Synonym
gtpl676
bim 31006
[d-arg0,hyp3,d-phe7]bradykinin
bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-
npc-567
bradykinin, n2-d-arginyl-3-(trans-4-hydroxy-l-proline)-7-d-phenylalanine-
bradykinin, arg(0)-hyp(3)-phe(7)-
bradykinin, arg-hyp(3)-phe(7)-
npc 567
arg-3-hyp-7-phe-bradykinin
109333-26-8
CHEMBL446325 ,
chebi:73294 ,
dv64b0pleh ,
unii-dv64b0pleh
arg(0)-hyp(3)-phe(7)-bradykinin
[d-arg(0),hyp(3),d-phe(7)]bradykinin
d-arginyl-l-arginyl-l-prolyl-(4r)-4-hydroxy-l-prolylglycyl-l-phenylalanyl-l-seryl-d-phenylalanyl-l-phenylalanyl-l-arginine
bdbm50435301
d-arg-arg-pro-hyp-gly-phe-ser-d-phe-phe-arg
bim-31006
bradykinin, n2-d-arginyl-3-((4r)-4-hydroxy-l-proline)-7-d-phenylalanine-
Q27088026
HY-P2118
CS-0108808
AKOS040744757

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"We wished to determine whether enhanced bioavailability of bradykinin (BK) and vasodilatory prostaglandins contribute to renovascular and sodium-handling effects of angiotensin-converting enzyme (ACE) inhibition after myocardial infarction (MI)."( Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction.
Deck, CC; Gaballa, MA; Raya, TE, 1996
)
0.29
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" histamine, characterized by a left shift in the dose-response curve."( Effects of bradykinin receptor antagonists on antigen-induced respiratory distress, airway hyperresponsiveness and eosinophilia in guinea-pigs.
Farmer, SG; Meeker, SA; Page, CP; Seeds, EA; Wilkins, DE, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bradykinin receptor antagonistAn antagonist at the bradykinin receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
B2 bradykinin receptorHomo sapiens (human)IC50 (µMol)0.01130.00040.02120.2800AID1285620; AID1336312; AID340239; AID752254
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
smooth muscle contractionB2 bradykinin receptorHomo sapiens (human)
inflammatory responseB2 bradykinin receptorHomo sapiens (human)
cell surface receptor signaling pathwayB2 bradykinin receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayB2 bradykinin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationB2 bradykinin receptorHomo sapiens (human)
blood circulationB2 bradykinin receptorHomo sapiens (human)
response to salt stressB2 bradykinin receptorHomo sapiens (human)
regulation of vasoconstrictionB2 bradykinin receptorHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationB2 bradykinin receptorHomo sapiens (human)
vasoconstrictionB2 bradykinin receptorHomo sapiens (human)
vasodilationB2 bradykinin receptorHomo sapiens (human)
regulation of vascular permeabilityB2 bradykinin receptorHomo sapiens (human)
arachidonic acid secretionB2 bradykinin receptorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediatorB2 bradykinin receptorHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediatorB2 bradykinin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayB2 bradykinin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protease bindingB2 bradykinin receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityB2 bradykinin receptorHomo sapiens (human)
bradykinin receptor activityB2 bradykinin receptorHomo sapiens (human)
protein bindingB2 bradykinin receptorHomo sapiens (human)
type 1 angiotensin receptor bindingB2 bradykinin receptorHomo sapiens (human)
protein heterodimerization activityB2 bradykinin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endosomeB2 bradykinin receptorHomo sapiens (human)
Golgi apparatusB2 bradykinin receptorHomo sapiens (human)
plasma membraneB2 bradykinin receptorHomo sapiens (human)
intracellular membrane-bounded organelleB2 bradykinin receptorHomo sapiens (human)
plasma membraneB2 bradykinin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID42981Antagonistic activity of compound was measured for bradykinin receptor in guinea pig ileum1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Probing the bradykinin receptor: mapping the geometric topography using ethers of hydroxyproline in novel peptides.
AID340239Inhibition of human bradykinin B2 receptor2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID1336312Displacement of [3H]bradykinin from human recombinant bradykinin B2 receptor expressed in CHO cells measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID201333Antagonistic activity of compound was measured in SV-T2 cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Probing the bradykinin receptor: mapping the geometric topography using ethers of hydroxyproline in novel peptides.
AID42980Binding affinity of compound was measured for bradykinin receptor in guinea pig ileum1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Probing the bradykinin receptor: mapping the geometric topography using ethers of hydroxyproline in novel peptides.
AID42976Binding affinity for bradykinin receptor of SV-T2 fibroblasts1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Design and conformational analysis of several highly potent bradykinin receptor antagonists.
AID752254Binding affinity to human bradykinin B2 receptor by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID1285620Displacement of [3H]bradykinin from human recombinant B2 bradykinin receptor2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID42974Displacement of [3H]bradykinin from bradykinin receptor in guinea pig ileal membrane1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Design and conformational analysis of several highly potent bradykinin receptor antagonists.
AID1346473Human B2 receptor (Bradykinin receptors)1994Molecular pharmacology, Jan, Volume: 45, Issue:1
Differential pharmacology of cloned human and mouse B2 bradykinin receptors.
AID1346510Mouse B2 receptor (Bradykinin receptors)1994Molecular pharmacology, Jan, Volume: 45, Issue:1
Differential pharmacology of cloned human and mouse B2 bradykinin receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (10.00)18.7374
1990's36 (72.00)18.2507
2000's6 (12.00)29.6817
2010's3 (6.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.14 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (3.85%)5.53%
Reviews1 (1.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (94.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]